适用于福尔马林固定石蜡包埋活检的套细胞淋巴瘤增殖特征新型分子检测
研究在NanoString平台训练并验证了MCL35检测,用于从福尔马林固定石蜡包埋活检中测量增殖特征。在110例接受利妥昔单抗联合CHOP方案治疗的患者中,MCL35将患者分为高危(26%)、标危(29%)和低危(45%)三组,中位总生存期分别为1.1年、2.6年和8.6年(趋势检验P<.001),且三实验室风险分组一致性为100%。
要点
- MCL35检测可在98%(108/110)的石蜡包埋活检中成功评分并划分风险组。
- 高危、标危、低危组中位总生存期分别为1.1年、2.6年和8.6年(趋势检验P<.001)。
- 风险分组与套细胞淋巴瘤国际预后指数均与总生存期独立相关(P<.001)。
核心结论
- 新开发并验证的MCL35检测利用增殖特征定义总生存期显著不同的患者组,且独立于套细胞淋巴瘤国际预后指数。
- 该检测的分析及临床有效性定义其为支持风险适应性临床试验的可靠生物标志物。
研究设计与样本
- 研究使用47例福尔马林固定石蜡包埋活检在NanoString平台上训练检测,以配对新鲜冷冻活检的微阵列基因表达数据为金标准。
- 锁定后的检测应用于独立队列110例统一接受利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松治疗的 pretreatment 福尔马林固定石蜡包埋淋巴结活检。
- 17例活检在三个实验室间测试以评估检测可重复性。
主要发现
- MCL35检测包含17基因增殖特征,在108例(98%)的110例存档石蜡包埋活检中产生足够质量的基因表达以分配检测评分和风险组。
- MCL35将患者分为高危(26%)、标危(29%)和低危(45%)组,中位总生存期分别为1.1年、2.6年和8.6年(趋势检验P<.001)。
- 多变量分析中,风险分组和套细胞淋巴瘤国际预后指数均与总生存期独立相关(两者P<.001)。
- 三个独立实验室间风险分组一致性为100%。
关键数值与推荐
- MCL35检测包含17基因增殖特征。
- 高危组占26%,中位总生存期1.1年;标危组占29%,中位总生存期2.6年;低危组占45%,中位总生存期8.6年(趋势检验P<.001)。
- 风险分组和套细胞淋巴瘤国际预后指数与总生存期独立相关(P<.001)。
- 三实验室风险分组一致性100%。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Mantle cell lymphoma is an aggressive B-cell neoplasm that displays heterogeneous outcomes after treatment. In 2003, the Lymphoma/Leukemia Molecular Profiling Project described a powerful biomarker-the proliferation signature-using gene expression in fresh frozen material. Herein, we describe the training and validation of a new assay that measures the proliferation signature in RNA derived from routinely available formalin-fixed paraffin-embedded (FFPE) biopsies. Methods Forty-seven FFPE biopsies were used to train an assay on the NanoString platform, using microarray gene expression data of matched fresh frozen biopsies as a gold standard. The locked assay was applied to pretreatment FFPE lymph node biopsies from an independent cohort of 110 patients uniformly treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Seventeen biopsies were tested across three laboratories to assess assay reproducibility. Results The MCL35 assay, which contained a 17-gene proliferation signature, yielded gene expression of sufficient quality to assign an assay score and risk group in 108 (98%) of 110 archival FFPE biopsies. The MCL35 assay assigned patients to high-risk (26%), standard-risk (29%), and low-risk (45%) groups, with different lengths of overall survival (OS): a median of 1.1, 2.6, and 8.6 years, respectively (log-rank for trend, P < .001). In multivariable analysis, these risk groups and the Mantle Cell Lymphoma International Prognostic Index were independently associated with OS ( P < .001 for both variables). Concordance of risk assignment across the three independent laboratories was 100%. Conclusion The newly developed and validated MCL35 assay for FFPE biopsies uses the proliferation signature to define groups of patients with significantly different OS independent of the Mantle Cell Lymphoma International Prognostic Index. Importantly, the analytic and clinical validity of this assay defines it as a reliable biomarker to support risk-adapted clinical trials.
引用
- Scott DW, Abrisqueta P, Wright GW, et al. New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. J Clin Oncol. 2017. PMID: 28291392. doi:10.1200/JCO.2016.70.7901
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。